Pozen and Glaxo score FDA approval for migraine treatment drug
Shares of Pozen Inc. (Nasdaq:POZN) are rocketing this morning after the small cap pharmaceutical company said that it, along with GlaxoSmithKline (NYSE:GSK), has received approval from the Food and Drug Administration for Treximet, a tablet that treats migraine attacks with or without aura in adults.
Shares rocketed 39%, or $4.12, to $14.65 in pre-market trading. For detailed price information and recent news stories about Pozen, click POZN.
